These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1706409)

  • 1. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine.
    Snijders A; Benaissa-Trouw BJ; Oosterlaken TA; Puijk WC; Posthumus WP; Meloen RH; Boere WA; Oosting JD; Kraaijeveld CA; Snippe H
    J Gen Virol; 1991 Mar; 72 ( Pt 3)():557-65. PubMed ID: 1706409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vaccine against Semliki Forest virus consisting of a monoclonal anti-idiotypic antibody cross-linked to a protein which contains virus-specific T-helper cell epitopes.
    Kraaijeveld CA; Oosterlaken TA; Snijders A; Benaissa-Trouw BJ; Ekstijn GL; Snippe H
    Antiviral Res; 1992 Oct; 19(4):275-84. PubMed ID: 1281391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
    Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA
    J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes.
    Snijders A; Benaissa-Trouw BJ; Snippe H; Kraaijeveld CA
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2267-72. PubMed ID: 1383405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge.
    Grosfeld H; Velan B; Leitner M; Cohen S; Lustig S; Lachmi BE; Shafferman A
    J Virol; 1989 Aug; 63(8):3416-22. PubMed ID: 2473217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.
    Snijders A; Benaissa-Trouw BJ; Visser-Vernooy HJ; Fernandez I; Snippe H; Kraaijeveld CA
    Immunology; 1992 Nov; 77(3):322-9. PubMed ID: 1282493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus.
    Grosfeld H; Velan B; Leitner M; Lustig S; Lachi BE; Cohen S; Shafferman A
    Vaccine; 1991 Jun; 9(6):451-6. PubMed ID: 1716035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on linear epitopes of Semliki Forest virus in protection studies against lethal challenge virus infection.
    Truyen U; Kaaden OR
    Zentralbl Veterinarmed B; 1991 Aug; 38(6):463-7. PubMed ID: 1719714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.
    Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA
    Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologically defined linear epitopes in the E2 envelope glycoprotein of Semliki Forest virus.
    Ariel N; Lehrer S; Elhanaty E; Sabo T; Brodt P; Lachmi B; Katz D; Levin R; Grosfeld H; Velan B
    Arch Virol; 1990; 113(1-2):99-106. PubMed ID: 1696808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A shared idiotope among antibodies against Semliki Forest virus.
    Fernández IM; Ovaa W; Harmsen M; Benaissa-Trouw BJ; Bos NA; Kraaijeveld CA; Snippe H
    Viral Immunol; 1994; 7(2):71-80. PubMed ID: 7531444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent envelope E2 alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cytolytic activity.
    Grosfeld H; Lustig S; Gozes Y; Velan B; Cohen S; Leitner M; Lachmi B; Katz D; Olshevski U; Shafferman A
    J Virol; 1992 Feb; 66(2):1084-90. PubMed ID: 1309890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities.
    Boere WA; Harmsen T; Vinjé J; Benaissa-Trouw BJ; Kraaijeveld CA; Snippe H
    J Virol; 1984 Nov; 52(2):575-82. PubMed ID: 6208379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus.
    Boere WA; Benaissa-Trouw BJ; Harmsen T; Erich T; Kraaijeveld CA; Snippe H
    Immunology; 1986 Aug; 58(4):553-9. PubMed ID: 3015781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to spike protein vaccines prepared from Semliki Forest virus.
    Balcarova J; Helenius A; Simons K
    J Gen Virol; 1981 Mar; 53(Pt 1):85-92. PubMed ID: 6268742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice.
    Oosterlaken TA; Harmsen M; Jhagjhoor-Singh SS; Ekstijn GL; Kraaijeveld CA; Snippe H
    J Virol; 1991 Jan; 65(1):98-102. PubMed ID: 1845911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgVH determined genetic restriction of a non-internal image monoclonal anti-idiotypic vaccine against Semliki Forest virus.
    Oosterlaken TA; Harmsen M; Ekstijn GL; Kraaijeveld CA; Snippe H
    Immunology; 1992 Feb; 75(2):224-31. PubMed ID: 1551685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles.
    Brand D; Lemiale F; Turbica I; Buzelay L; Brunet S; Barin F
    AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1369-77. PubMed ID: 9788678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.
    Fleeton MN; Liljeström P; Sheahan BJ; Atkins GJ
    J Gen Virol; 2000 Mar; 81(Pt 3):749-58. PubMed ID: 10675413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.